Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
33.98
+1.45 (4.46%)
Nov 1, 2024, 4:00 PM EDT - Market closed
Spyre Therapeutics Employees
Spyre Therapeutics had 30 employees as of December 31, 2023. The number of employees decreased by 39 or -56.52% compared to the previous year.
Employees
30
Change (1Y)
-39
Growth (1Y)
-56.52%
Revenue / Employee
n/a
Profits / Employee
-$6,199,367
Market Cap
1.73B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Myriad Genetics | 2,700 |
NovoCure | 1,453 |
Certara | 1,391 |
AtriCure | 1,200 |
Galapagos NV | 1,123 |
BioCryst Pharmaceuticals | 536 |
Nurix Therapeutics | 284 |
Celldex Therapeutics | 160 |
SYRE News
- 1 day ago - Spyre Therapeutics Announces Grants of Inducement Awards - PRNewsWire
- 3 days ago - Spyre Therapeutics to Participate in Upcoming November Investor Conferences - PRNewsWire
- 20 days ago - Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations - PRNewsWire
- 4 weeks ago - Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting - Seeking Alpha
- 4 weeks ago - Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer - PRNewsWire
- 7 weeks ago - Spyre Therapeutics to Participate in Upcoming Investor Conference - PRNewsWire
- 3 months ago - Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 4 months ago - Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease - PRNewsWire